Evidence map›Paper›PMID 35082681›Full record

ArticleFrontiers in pharmacology2021

Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy.

Lei Ding, Ping Zhang, Xu Huang, Kunmeng Yang, Xingkai Liu, Zhenxiang Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Efficacy analysis of targeted nanodrug for non-small cell lung cancer therapy.Frontiers in bioengineering and biotechnology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lei DingDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Ping ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Xu HuangDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Kunmeng YangDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Xingkai LiuDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Zhenxiang YuDepartment of Respiration, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The stimuli-responsive polymer-based platform for controlled drug delivery has gained increasing attention in treating hepatocellular carcinoma (HCC) owing to the fascinating biocompatibility and biodegradability, improved antitumor efficacy, and negligible side effects recently. Herein, a disulfide bond-contained polypeptide nanogel, methoxy poly(ethylene glycol)-poly(l-phenylalanine-

Indexed as

hepatocellular carcinomalenvatinibmolecular targeted therapypolypeptidereduction-responsive nanomedicine

Identifiers

PMID35082681
PMCPMC8784786
OpenAlexW4206633266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.